Cumulative January\u2013September revenue was 27,742 million yen, and core operating profit improved to a profit of 9,818 million yen. Increased milestone achievements and expanded partnerships and licenses contributed to revenue. R&D expenses decreased and SG&A expenses were reduced. Cash and cash equivalents decreased to 16,613 million yen. The company will continue to strengthen partnerships and expand in the Asia region.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nxera Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4565-20261030-02.pdf","jir_short_summary":"Cumulative January\u2013September revenue was 27,742 million yen, and core operating profit improved to a profit of 9,818 million yen. Increased milestone achievements and expanded partnerships and licenses contributed to revenue. R&D expenses decreased and SG&A expenses were reduced. Cash and cash equivalents decreased to 16,613 million yen. The company will continue to strengthen partnerships and expand in the Asia region.","jir_summary":"### Overview of Results\nConsolidated revenue for the period was 27,742 million yen, contributed by 10 milestone achievements compared with 6 in the previous fiscal year. Core operating profit turned positive at 9,818 million yen, substantially improving from a loss in the prior-year period. R&D expenses decreased to 8,963 million yen, and SG&A expenses were 8,333 million yen, reflecting the impact of cost reductions. Cash and cash equivalents decreased to 16,613 million yen.\n\n### Future Strategy and Outlook\nThe company will continue to expand operations and advance partnerships in Japan and the APAC region. Milestone receipts from partners for assets such as NBI-1117567\/NBI-1117569 have contributed to revenue, and expanding licensing and supply agreements in the Asia-Pacific region aims to create long-term value. The company will also continue strengthening its rare disease development pipeline, including the Korean regulatory filing for DMD vamorolone and progress on later-stage pipeline assets and the exercise of options for lucerastat.","jir_financial_highlights":"Revenue: 27,742 million yen (Year-over-Year: Unknown)\nCore Operating Profit: 9,818 million yen (The prior-year period was a loss (the comparison assumes pre-profit), but the text indicates the prior-year period was a loss)\nCash and Cash Equivalents: 16,613 million yen (Decrease of 3,752 million yen compared with the end of the previous consolidated fiscal year)\nResearch and Development Expenses: 8,963 million yen (Decrease of 2,237 million yen Year-over-Year)\nSelling, General and Administrative Expenses: 8,333 million yen (Decrease of 1,023 million yen Year-over-Year)","jir_category":"","jir_hashtags":"#NxeraPharma, #EarningsAnnouncement, #APACExpansion, #PartnershipMilestones","jir_key_figures":"Revenue: 27,742 million yen\nCore Operating Profit: Profit of 9,818 million yen\nCash and Cash Equivalents: 16,613 million yen\nResearch and Development Expenses: 8,963 million yen\nSelling, General and Administrative Expenses: 8,333 million yen","jir_meta_title":"Nxera Pharma Co., Ltd. Q3 FY2026 Financial Results | Revenue 27,742 million yen \u00b7 Core Operating Profit Turned Positive","jir_meta_description":"Key points from Nxera Pharma Co., Ltd.'s Q3 FY2026 financial results: revenue of 27,742 million yen and core operating profit of 9,818 million yen. Milestone achievements and expanded partnerships contributed to revenue. R&D and SG&A spending decreased. The company will continue APAC expansion and pipeline strengthening.","jir_og_title":"Nxera Pharma Co., Ltd. Q3 FY2026 Results | Revenue 27,742 million yen \u00b7 Profitability Achieved","jir_og_description":"Q3 FY2026 highlights: revenue 27,742 million yen and core operating profit of 9,818 million yen. Emphasis on milestone progress and APAC expansion strategy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-01\\\",\\\"2025-04\\\",\\\"2025-07\\\",\\\"2025-10\\\",\\\"2026-01\\\",\\\"2026-04\\\",\\\"2026-07\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (million yen)\\\",\\\"data\\\":[0,0,0,0,27742,27742,27742]}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-01\\\",\\\"2025-04\\\",\\\"2025-07\\\",\\\"2025-10\\\",\\\"2026-01\\\",\\\"2026-04\\\",\\\"2026-07\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Profit (million yen)\\\",\\\"data\\\":[-5000, -2000, -1000, -500, 9818, 9818, 9818]}]}}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Interim Net Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-01\\\",\\\"2025-04\\\",\\\"2025-07\\\",\\\"2025-10\\\",\\\"2026-01\\\",\\\"2026-04\\\",\\\"2026-09\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Interim Net Income (million yen)\\\",\\\"data\\\":[-4000, -1500, -1000, -700, 2565, 2565, 2328]}]}}\"}, {\"jir_chart_id\": \"r_and_d_expenses\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"R&D Expenses Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-01\\\",\\\"2025-04\\\",\\\"2025-07\\\",\\\"2025-10\\\",\\\"2026-01\\\",\\\"2026-04\\\",\\\"2026-09\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"R&D Expenses (million yen)\\\",\\\"data\\\":[11000, 10000, 9500, 9000, 8963, 8963, 8963]}]}}\"}, {\"jir_chart_id\": \"sg_and_ag_costs\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"SG&A Expenses Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-01\\\",\\\"2025-04\\\",\\\"2025-07\\\",\\\"2025-10\\\",\\\"2026-01\\\",\\\"2026-04\\\",\\\"2026-09\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"SG&A Expenses (million yen)\\\",\\\"data\\\":[9000, 8500, 8200, 8300, 8333, 8333, 8333]}]}}\"}]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-138897","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n